Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease
Identifieur interne : 009E76 ( Main/Exploration ); précédent : 009E75; suivant : 009E77Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease
Auteurs : Thomas Feyerabend [Allemagne] ; Günter Joseph Wiedemann [Allemagne] ; Birgit J Ger [Allemagne] ; Hugo Vesely [Allemagne] ; Birgit Mahlmann [Allemagne] ; Eckart Richter [Allemagne]Source :
- International Journal of Radiation Oncology, Biology, Physics [ 0360-3016 ] ; 2001.
English descriptors
Abstract
Purpose: To investigate the feasibility and effectiveness of radiochemothermotherapy (triple-modality therapy) in patients with inoperable recurrent breast cancer. Patients and Methods: Patients with inoperable recurrent lesions, World Health Organization (WHO) performance status of 2 or greater, life expectancy of more than 3 months, adequate bone marrow, hepatic and renal function were eligible for this Phase I/II study. Conventionally fractionated or hyperfractionated radiotherapy (RT) was performed. Once-weekly local hyperthermia (HT) combined with chemotherapy (CT; epirubicin 20 mg/m2, ifosfamide 1.5 g/m2) was applied within 30 min after RT. Results: Twenty-five patients, all heavily pretreated (18/25 preirradiated), received a mean total dose of 49 Gy. The median number of HT/CT sessions was 4. Skin toxicity was low, whereas bone marrow toxicity was significant (leucopenia Grade 3/4 in 14/1 patients). The overall response rate was 80% with a complete response (CR) rate of 44%. Response rates in patients with noninflammatory disease (n = 14; CR 10 patients, partial response [PR] 3 patients) were far better than in patients with inflammatory disease (n = 11; CR 1 patient, PR 6 patients). Conclusions: In patients with recurrent breast cancer, triple-modality therapy is feasible with acceptable toxicity. High remission rates can be achieved in noninflammatory disease, however, local control is limited to a few months. Whether the addition of chemotherapy has a clear-cut advantage to radiothermotherapy alone remains an open question.
Url:
DOI: 10.1016/S0360-3016(00)01514-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004987
- to stream Istex, to step Curation: 004987
- to stream Istex, to step Checkpoint: 002B79
- to stream Main, to step Merge: 00A329
- to stream Main, to step Curation: 009E76
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease</title><author><name sortKey="Feyerabend, Thomas" sort="Feyerabend, Thomas" uniqKey="Feyerabend T" first="Thomas" last="Feyerabend">Thomas Feyerabend</name></author><author><name sortKey="Wiedemann, Gunter Joseph" sort="Wiedemann, Gunter Joseph" uniqKey="Wiedemann G" first="Günter Joseph" last="Wiedemann">Günter Joseph Wiedemann</name></author><author><name sortKey="J Ger, Birgit" sort="J Ger, Birgit" uniqKey="J Ger B" first="Birgit" last="J Ger">Birgit J Ger</name></author><author><name sortKey="Vesely, Hugo" sort="Vesely, Hugo" uniqKey="Vesely H" first="Hugo" last="Vesely">Hugo Vesely</name></author><author><name sortKey="Mahlmann, Birgit" sort="Mahlmann, Birgit" uniqKey="Mahlmann B" first="Birgit" last="Mahlmann">Birgit Mahlmann</name></author><author><name sortKey="Richter, Eckart" sort="Richter, Eckart" uniqKey="Richter E" first="Eckart" last="Richter">Eckart Richter</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9CAF5A595141DF562824C9BA83D712280D1DCA3F</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0360-3016(00)01514-5</idno><idno type="url">https://api.istex.fr/document/9CAF5A595141DF562824C9BA83D712280D1DCA3F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004987</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004987</idno><idno type="wicri:Area/Istex/Curation">004987</idno><idno type="wicri:Area/Istex/Checkpoint">002B79</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002B79</idno><idno type="wicri:doubleKey">0360-3016:2001:Feyerabend T:local:hyperthermia:radiation</idno><idno type="wicri:Area/Main/Merge">00A329</idno><idno type="wicri:Area/Main/Curation">009E76</idno><idno type="wicri:Area/Main/Exploration">009E76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease</title><author><name sortKey="Feyerabend, Thomas" sort="Feyerabend, Thomas" uniqKey="Feyerabend T" first="Thomas" last="Feyerabend">Thomas Feyerabend</name><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology and Nuclear Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Wiedemann, Gunter Joseph" sort="Wiedemann, Gunter Joseph" uniqKey="Wiedemann G" first="Günter Joseph" last="Wiedemann">Günter Joseph Wiedemann</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="J Ger, Birgit" sort="J Ger, Birgit" uniqKey="J Ger B" first="Birgit" last="J Ger">Birgit J Ger</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology and Nuclear Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Vesely, Hugo" sort="Vesely, Hugo" uniqKey="Vesely H" first="Hugo" last="Vesely">Hugo Vesely</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology and Nuclear Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Mahlmann, Birgit" sort="Mahlmann, Birgit" uniqKey="Mahlmann B" first="Birgit" last="Mahlmann">Birgit Mahlmann</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology and Nuclear Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Richter, Eckart" sort="Richter, Eckart" uniqKey="Richter E" first="Eckart" last="Richter">Eckart Richter</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology and Nuclear Medicine, Medical University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Radiation Oncology, Biology, Physics</title><title level="j" type="abbrev">ROB</title><idno type="ISSN">0360-3016</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1317">1317</biblScope><biblScope unit="page" to="1325">1325</biblScope></imprint><idno type="ISSN">0360-3016</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-3016</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cisplatin</term><term>Ifosfamide</term><term>Local hyperthermia</term><term>Radiation</term><term>Recurrent breast cancer</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To investigate the feasibility and effectiveness of radiochemothermotherapy (triple-modality therapy) in patients with inoperable recurrent breast cancer. Patients and Methods: Patients with inoperable recurrent lesions, World Health Organization (WHO) performance status of 2 or greater, life expectancy of more than 3 months, adequate bone marrow, hepatic and renal function were eligible for this Phase I/II study. Conventionally fractionated or hyperfractionated radiotherapy (RT) was performed. Once-weekly local hyperthermia (HT) combined with chemotherapy (CT; epirubicin 20 mg/m2, ifosfamide 1.5 g/m2) was applied within 30 min after RT. Results: Twenty-five patients, all heavily pretreated (18/25 preirradiated), received a mean total dose of 49 Gy. The median number of HT/CT sessions was 4. Skin toxicity was low, whereas bone marrow toxicity was significant (leucopenia Grade 3/4 in 14/1 patients). The overall response rate was 80% with a complete response (CR) rate of 44%. Response rates in patients with noninflammatory disease (n = 14; CR 10 patients, partial response [PR] 3 patients) were far better than in patients with inflammatory disease (n = 11; CR 1 patient, PR 6 patients). Conclusions: In patients with recurrent breast cancer, triple-modality therapy is feasible with acceptable toxicity. High remission rates can be achieved in noninflammatory disease, however, local control is limited to a few months. Whether the addition of chemotherapy has a clear-cut advantage to radiothermotherapy alone remains an open question.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Feyerabend, Thomas" sort="Feyerabend, Thomas" uniqKey="Feyerabend T" first="Thomas" last="Feyerabend">Thomas Feyerabend</name></noRegion><name sortKey="Feyerabend, Thomas" sort="Feyerabend, Thomas" uniqKey="Feyerabend T" first="Thomas" last="Feyerabend">Thomas Feyerabend</name><name sortKey="J Ger, Birgit" sort="J Ger, Birgit" uniqKey="J Ger B" first="Birgit" last="J Ger">Birgit J Ger</name><name sortKey="Mahlmann, Birgit" sort="Mahlmann, Birgit" uniqKey="Mahlmann B" first="Birgit" last="Mahlmann">Birgit Mahlmann</name><name sortKey="Richter, Eckart" sort="Richter, Eckart" uniqKey="Richter E" first="Eckart" last="Richter">Eckart Richter</name><name sortKey="Vesely, Hugo" sort="Vesely, Hugo" uniqKey="Vesely H" first="Hugo" last="Vesely">Hugo Vesely</name><name sortKey="Wiedemann, Gunter Joseph" sort="Wiedemann, Gunter Joseph" uniqKey="Wiedemann G" first="Günter Joseph" last="Wiedemann">Günter Joseph Wiedemann</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009E76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009E76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9CAF5A595141DF562824C9BA83D712280D1DCA3F
|texte= Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease
}}
| This area was generated with Dilib version V0.6.31. |  |